Dr. Cantor’s pioneering studies on CD98 in adaptive immunity have shed light on the connection between adhesive signaling and nutrient transport in lymphocyte clonal expansion. CD98 and other integrin-associated proteins govern the expansion and migration of T and B cells in ways that strongly regulate protective immunity, autoimmunity, and anti-tumor immunity. The Cantor lab is currently investigating how CD98 is regulated, how CD98 controls lymphocyte proliferation, and how this protein could be exploited to boost weak protective immunity or prevent/treat autoimmunity. His research has also expanded to study how modulating integrin-associated proteins could improve adoptive immunotherapy for cancer.
Recent publications include
Endothelial Cells Require CD98 for Efficient Angiogenesis. Atherosclerosis, Thrombosis, and Vascular Biology
Fine-tuning Tumor Immunity with Integrin Trans-regulation. Cancer Immunology Research
CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. Journal of Neuroimmunology
Recent grant support
Dr. Cantor is currently funded by an NIH K01 Award and a Melanoma Research Alliance Young Investigator Award.